WXWH-0226 is under clinical development by Guizhou Inochini Technology and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WXWH-0226’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
WXWH-0226 overview
WXWH-0226 is under development for the treatment of Parkinson's disease. The drug candidate acts by targeting leucine-rich repeat kinase 2 (LRRK2) and is administered through oral route in the form of tablets.
Guizhou Inochini Technology overview
Guizhou Inochini Technology is a biopharmaceutical company engaged in research, development, production and marketing of innovative small molecule targeted drugs to treat Parkinson’s disease. The company is headquartered in Guiyang, Guizhou, China.
For a complete picture of WXWH-0226’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.